ENLIVEN THERAPEUTICS, INC. Severance Costs
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Severance Costs of $1.90 million for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts1 · last filed 2023-02-10
- ENLIVEN THERAPEUTICS, INC. severance costs for the quarter ending 2022-06-30 was $1.90M.
| Period end | Severance Costs | Severance Costs 3 month | Severance Costs 6 month |
|---|---|---|---|
| 2022-06-30 | $1.90M 10-Q · filed 2022-08-03 | $1.90M 10-Q · filed 2022-08-03 | |
| 2022-04-12 | $2.10M 10-K · filed 2023-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |